global glp-1 obesity drug market size forecast 2030 Analogues Report, Growth and GLP-1 Market Size, Share |

Anybody who has A BMI over 35 should qualify for this program

In the SUSTAIN trials, semaglutide-treated patients achieved mean weight reductions of 10-15% of baseline body weight, with some reaching 20%+ loss at higher doses

Nat Med (2022) 28:5918

This suggests that GLP-1 may have cardiovascular protective properties

Next-Generation Oral Small-Molecule GLP-1s Unlocking Primary-Care and Emerging-Market Volume Orforglipron, GSBR-1290, and VK2735 demonstrated double-digit weight-loss efficacy in Phase 2 studies without injection-related barriers, attracting strong interest from primary-care physicians

Physiol Behav 100 , 503510, (2010)